US Army to participate in Neuren phase III trials
24 November, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX:NEU) has executed a memorandum of understanding (MOU) with the Henry M. Jackson Foundation for the Advancement of Military Medicine for inclusion of US Army hospital sites in Neuren's phase III trial of its lead drug Glypromate.
Probiomics to commence flu vaccine trial
24 November, 2005 by Ruth BeranProbiomics' (ASX:PCC) shares increased by more than 25 per cent yesterday on news that the company will undertake a clinical trial to examine the ability of its proprietary probiotic strain PCC to boost the immune response to a vaccine for influenza.
Fast composter for city waste
23 November, 2005 by Graeme O'NeillResearchers from the Environmental Biotechnology Cooperative Research Centre (EBCRC) have successfully tested a, self-sustaining process that rapidly composts municipal solid wastes.
Norwood commences phase II cancer vaccine trial
21 November, 2005 by Graeme O'NeillMelbourne meditech Norwood Immunology (AIM:NIM) has recruited the first of 100 post-surgical melanoma patients into a phase II clinical trial of its thymus-rejuvenating technology, using the gonadotrophin releasing hormone (GNRH) analogue Lupron Depot.
National bioprospecting regulations released
21 November, 2005 by Ruth BeranThe Australian government has released new national environmental regulations to control 'bioprospecting' -- the search for new chemicals in living things that will have some medical or commercial use.
CSIRO abandons GM pea project
18 November, 2005 by Graeme O'NeillCSIRO Plant Industry researchers have abandoned a project to develop a genetically modified field pea with resistance to the pea weevil, Bruchus pisorum.
Novogen pleased by cancer drug results
18 November, 2005 by Ruth BeranTrials of Novogen's (ASX:NRT) anti-cancer drug phenoxodiol have shown it significantly delays tumour progression in men suffering from late-stage hormone refractory prostate cancer and produces anti-cancer responses in women with cervical cancer.
OPINION: Taking advantage of our clinical strengths
18 November, 2005 by Graeme BlackmanAustralia, take a bow -- you've proved you can compete in the global clinical trials market. But let's not get too complacent, writes Graeme Blackman.
REPORT: How we score on pharma R&D
18 November, 2005 by Ruth BeranRuth Beran wraps up a recent report that gives Australia a high rating against other major centres of pharma R&D.
Aust CROs tell of boom in clinical trials work
18 November, 2005 by Ruth BeranRuth Beran spoke with Australian contract research organisations and found that there is strong demand for Australian clinical trials, both from within Australia and also from overseas.
New research shows Aussie lizard bites can really hurt
17 November, 2005 by Graeme O'NeillAustralian venom researchers have uncovered a 200-million year old secret: Australia's goannas and bearded dragons, Indonesia's giant Komodo dragon, and their iguana cousins, are more closely related to snakes than to other lizards -- and they're venomous.
Metabolic reports successful phase I trials
16 November, 2005 by Graeme O'NeillMelbourne biopharma Metabolic (ASX:MBP) has announced plans to take its ACV1 conotoxin analgesic into phase IIa clinical trial in volunteers with chronic neuropathic pain next year.
Phosphagenics aims to raise $11.25m
15 November, 2005 by Helen SchullerMelbourne's Phosphagenics (ASX:POH, AIM:PSG) is planning to raise AUD$11.25 million via a share placement to fund its core R&D program.
CyGenics to team with Johns Hopkins
15 November, 2005 by Helen SchullerCell therapy company CyGenics (ASX:CYN) and Johns Hopkins University School of Medicine have entered into a collaborative research agreement as part of a pre-clinical study directed at a new treatment strategy for patients with acute myeloid leukaemia (AML).
Starpharma raises $15m
15 November, 2005 by Helen SchullerMelbourne drug developer Starpharma (ASX:SPL) has successfully raised AUD$12 million through an institutional placement at $0.51 and an additional $3 million following an underwritten share purchase plan.
